Centrient Pharmaceuticals
Centrient Pharmaceuticals, headquartered in the Netherlands, is a leading player in the global pharmaceutical industry, specialising in the development and manufacturing of essential antibiotics and anti-infectives. Founded in 2017, the company has quickly established itself as a key provider of high-quality, sustainable pharmaceutical solutions, with a strong operational presence across Europe, Asia, and North America. Centrient's core offerings include a diverse range of generic and branded antibiotics, as well as innovative formulations that address critical healthcare needs. The company is recognised for its commitment to sustainability and responsible manufacturing practices, setting it apart in a competitive market. With a focus on quality and patient safety, Centrient Pharmaceuticals continues to achieve significant milestones, reinforcing its position as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Centrient Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Centrient Pharmaceuticals's score of 53 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Centrient Pharmaceuticals's reported carbon emissions
In 2024, Centrient Pharmaceuticals reported total carbon emissions of approximately 697,019,000 kg CO2e. This figure includes 142,884,000 kg CO2e from Scope 1 emissions, 118,053,000 kg CO2e from Scope 2 emissions, and 436,083,000 kg CO2e from Scope 3 emissions, with the latter primarily driven by purchased goods and services, accounting for about 289,710,000 kg CO2e. Comparatively, in 2023, the company recorded total emissions of about 732,956,000 kg CO2e, indicating a reduction in emissions year-on-year. The breakdown for 2023 shows 143,291,000 kg CO2e from Scope 1, 141,432,000 kg CO2e from Scope 2, and 448,232,000 kg CO2e from Scope 3. Centrient Pharmaceuticals has set ambitious climate commitments, aiming for a 35% reduction in carbon emission intensity by 2025 and a 50% reduction by 2030, using 2015 as the baseline year. Additionally, the company has committed to an absolute reduction of 46.2% in Scope 1 and 2 greenhouse gas emissions by 2031, based on 2022 levels. For Scope 3 emissions, a target of a 27.5% reduction has been established for the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Centrient's commitment to sustainable practices within the pharmaceuticals sector. The company is actively working towards these goals, demonstrating a proactive approach to mitigating climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 87,494,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 202,885,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Centrient Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
